Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.
Axsome Therapeutics, Inc (AXSM) News
Latest headlines that mention AXSM, newest first · each headline opens the original publisher
- Last price
- $170.08
- Day change
- -1.67%
- Next earnings
- 2026-11-02
AXSM headlines
last 30 daysVertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.
Or are its best days in the rearview mirror?
One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases to target.
Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.
The stock slipped about 15% over the past three months.
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
Also mentioned with AXSM
30dHeadlines that tag both tickers
AXSM news alerts
Get an alert by email or push when a new headline mentions AXSM.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.